RT Journal Article
SR Electronic
T1 At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.20.22271237
DO 10.1101/2022.02.20.22271237
A1 Singanallur, Nagendrakumar B
A1 van Vuren, Petrus Jansen
A1 McAuley, Alexander J
A1 Bruce, Matthew P
A1 Kuiper, Michael J
A1 Gwini, Stella M
A1 Riddell, Shane
A1 Goldie, Sarah
A1 Drew, Trevor W
A1 Blasdell, Kim R
A1 Tachedjian, Mary
A1 Mangalaganesh, Shruthi
A1 Chahal, Simran
A1 Caly, Leon
A1 Druce, Julian D
A1 Juno, Jennifer A
A1 Kent, Stephen J
A1 Wheatley, Adam K
A1 Vasan, Seshadri S
YR 2022
UL http://medrxiv.org/content/early/2022/04/15/2022.02.20.22271237.abstract
AB Plasma samples taken at different time points from donors who received either AstraZeneca (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19) vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50% neutralizing antibody titres (NT50) against Delta and VIC31 at 6 months compared to 2 weeks after the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender were not found to significantly impact our results. These findings indicate that vaccine matching may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient neutralising antibodies against emerging variants of concern, especially Omicron, amidst the challenges of ensuring vaccine equity worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO Precision Health & Responsible Innovation Future Science Platforms, National Health and Medical Research Council (grant MRF2009092), and United States Food and Drug Administration (FDA) Medical Countermeasures Initiative (contract 75F40121C00144). J.A.J., S.J.K. and A.K.W. are grateful to the National Health and Medical Research Council (for grants GNT2002073, MRF2005544, GNT1149990, fellowships and an investigator grant). We also thank the Victorian Government, especially the Victorian Department of Health and Human Services, the major funder of the Victorian Infectious Diseases Reference Laboratory and Barwon Health. The article reflects the views of the authors and does not represent the views or policies of the funding agencies including the FDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional ethics committee of the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (University of Melbourne Central Human Research Ethics Committee gave ethics approval for this work (reference number 2021-21198-15398-3). As this work is part of a prospective cohort study and not an interventional study, registration with ICMJE-approved registry is not required. Human research ethics committee of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) gave ethics approval for this work (reference number 2021_123_RR).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.